| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41388-019-0913-4 |
| P698 | PubMed publication ID | 31409900 |
| P50 | author | Paul A Stewart | Q89936915 |
| Niveditha Nerlakanti | Q91622604 | ||
| P2093 | author name string | John L Cleveland | |
| Conor C Lynch | |||
| Leah M Cook | |||
| Jeremy S Frieling | |||
| Karen L Burger | |||
| Jeremy J McGuire | |||
| P2860 | cites work | TGF-β family signaling in stem cells | Q28274611 |
| Bone morphogenetic proteins | Q28300236 | ||
| Wnt5a is required for proper mammary gland development and TGF-beta-mediated inhibition of ductal growth | Q28505930 | ||
| Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos | Q28508310 | ||
| Type III transforming growth factor beta receptor regulates vascular and osteoblast development during palatogenesis | Q28592403 | ||
| PANTHER: a library of protein families and subfamilies indexed by function | Q29547480 | ||
| A multigenic program mediating breast cancer metastasis to bone | Q29614308 | ||
| The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone | Q30299930 | ||
| Transforming Growth Factor-Beta in Osteolytic Breast Cancer Bone Metastases | Q30311918 | ||
| TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases | Q30429041 | ||
| The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. | Q30487886 | ||
| An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer | Q33620502 | ||
| TGF-beta regulates the mechanical properties and composition of bone matrix | Q34245000 | ||
| Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells | Q34340236 | ||
| RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. | Q34494714 | ||
| Regulation of bone mass by Wnt signaling | Q34576629 | ||
| Role of non-canonical Wnt signaling in osteoblast maturation on microstructured titanium surfaces. | Q34873239 | ||
| Wnt5a as an effector of TGFβ in mammary development and cancer | Q35022625 | ||
| The type III TGF-beta receptor suppresses breast cancer progression | Q35191593 | ||
| Transforming growth factor-beta1 to the bone | Q36131663 | ||
| Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype | Q36236452 | ||
| Bone metastasis and the metastatic niche | Q36259458 | ||
| Current and emerging therapies for bone metastatic castration-resistant prostate cancer | Q36358303 | ||
| Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer | Q36516410 | ||
| Evidence for the involvement of protein kinase activity in transforming growth factor-beta signal transduction | Q36808476 | ||
| TGF-β mediates homing of bone marrow-derived human mesenchymal stem cells to glioma stem cells | Q36818228 | ||
| TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation | Q37307155 | ||
| Roles of TGF-beta family signaling in stem cell renewal and differentiation | Q37359959 | ||
| Bone marrow mesenchymal stem cells and TGF-β signaling in bone remodeling | Q37524243 | ||
| Amplified RNA synthesized from limited quantities of heterogeneous cDNA. | Q37705357 | ||
| Targeting the transforming growth factor-beta signalling pathway in metastatic cancer | Q37716206 | ||
| TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling. | Q37735525 | ||
| TGF-β in cancer and bone: implications for treatment of bone metastases | Q37779131 | ||
| Betaglycan: a multifunctional accessory | Q37873082 | ||
| TGF-β and its coreceptors in cancerogenesis: an overview | Q37959017 | ||
| Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases | Q38177689 | ||
| Altering the Proteoglycan State of Transforming Growth Factor β Type III Receptor (TβRIII)/Betaglycan Modulates Canonical Wnt/β-Catenin Signaling. | Q38736415 | ||
| WNT5A has anti-prostate cancer effects in vitro and reduces tumor growth in the skeleton in vivo | Q38956252 | ||
| Signaling Cross Talk between TGF-β/Smad and Other Signaling Pathways | Q39005862 | ||
| Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions | Q39085630 | ||
| The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer | Q40174236 | ||
| Betaglycan expression is transcriptionally up-regulated during skeletal muscle differentiation. Cloning of murine betaglycan gene promoter and its modulation by MyoD, retinoic acid, and transforming growth factor-beta | Q40694319 | ||
| Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. | Q41491922 | ||
| Abi3bp is a multifunctional autocrine/paracrine factor that regulates mesenchymal stem cell biology | Q41965313 | ||
| Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review) | Q42378297 | ||
| Betaglycan inhibits TGF-beta signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function | Q43773219 | ||
| Noncanonical WNT-5A signaling regulates TGF-β-induced extracellular matrix production by airway smooth muscle cells | Q43802195 | ||
| Comparison of human adult and fetal expression and identification of 535 housekeeping/maintenance genes | Q46136481 | ||
| Decreased TGFBR3/betaglycan expression enhances the metastatic abilities of renal cell carcinoma cells through TGF-β-dependent and -independent mechanisms. | Q48120175 | ||
| Wnt5a suppresses osteoblastic differentiation of human periodontal ligament stem cell-like cells via Ror2/JNK signaling | Q48168075 | ||
| Current perspectives on bone metastases in castrate-resistant prostate cancer | Q49285273 | ||
| WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages | Q49578198 | ||
| Thrombospondin-1 promotes mesenchymal stromal cell functions via TGFβ and in cooperation with PDGF. | Q51136254 | ||
| WNT5A and Its Receptors in the Bone-Cancer Dialogue. | Q51674853 | ||
| Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. | Q52594636 | ||
| Role of WNT5A receptors FZD5 and RYK in prostate cancer cells. | Q55332428 | ||
| Ligand-induced downregulation of receptors for TGF-beta in human osteoblast-like cells from adult donors | Q77767208 | ||
| Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo | Q84293881 | ||
| Wnt5a induces and maintains prostate cancer cells dormancy in bone | Q90796248 | ||
| P433 | issue | 44 | |
| P304 | page(s) | 6959-6969 | |
| P577 | publication date | 2019-08-13 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis | |
| P478 | volume | 38 |
Search more.